23rd Dec 2021 17:28
Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Says USD9 million milestone payment from AstraZeneca PLC triggered as a result of the initiation of a Phase 1 clinical trial of AZD5055, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis. "We are delighted that AstraZeneca is progressing AZD5055 (RXC006) into a Phase 1 study in healthy volunteers to support the further development in IPF," says Chief Executive Lisa Anson.
Current stock price: 82.25 pence, up 13% on Thursday
Year-to-date change: up 32%
By Lucy Heming; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaREDX.L